JTI IMI2 - Innovative Medicine Initiative 2
The goal of the Innovative Medicines Initiative 2 (IMI 2) programme is to develop next generation vaccines, medicines and treatments, such as new antibiotics. It will build on the successes and lessons learnt under IMI's first phase. As before, it will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators in collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe’s growing health challenges, and secure the future international competitiveness of Europe’s pharmaceutical industry. The total budget for the IMI 2 programme is €3.276 billion. The EU will contribute up to €1.638 billion of this from Horizon 2020, the EU research and innovation framework programme. EFPIA, the European Federation of Pharmaceutical Industries and Associations, will commit €1.425 billion in in kind contributions. In addition,other life science industries may contribute a further €213 million if they decide to join IMI 2 as members or as partners in individual projects.
https://www.uniud.it/it/struttura/programmi-aric/jti-innovative-medicine-initiative-2-imi2
https://www.uniud.it/@@site-logo/logo-uniud.svg
JTI IMI2 - Innovative Medicine Initiative 2
The goal of the Innovative Medicines Initiative 2 (IMI 2) programme is to develop next generation vaccines, medicines and treatments, such as new antibiotics. It will build on the successes and lessons learnt under IMI's first phase. As before, it will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators in collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe’s growing health challenges, and secure the future international competitiveness of Europe’s pharmaceutical industry. The total budget for the IMI 2 programme is €3.276 billion. The EU will contribute up to €1.638 billion of this from Horizon 2020, the EU research and innovation framework programme. EFPIA, the European Federation of Pharmaceutical Industries and Associations, will commit €1.425 billion in in kind contributions. In addition,other life science industries may contribute a further €213 million if they decide to join IMI 2 as members or as partners in individual projects.
